Companies advance tRNA therapeutics to overcome mutant stoppages in protein synthesis shared by thousands of genetic diseases and cancers.
But Alltrna is hardly alone in its pursuit of tRNA-based therapeutics. ReCode Therapeutics, Shape Therapeutics and Tevard Biosciences all came before it; and the field continues to expand with the arrival of hC Bioscience, a startup that emerged from stealth mode in late February with $24 million and a plan to fight cancer and rare diseases with tRNA.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only 8,40 € per issue
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
About this article
Cite this article
Dolgin, E. tRNA therapeutics burst onto startup scene.
Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01252-y